Skip to main content

Table 1 Clinical characteristics of participants

From: Increase in ACC GABA+ levels correlate with decrease in migraine frequency, intensity and disability over time

 

Migraine

(n = 18)

Demographics (mean ± SD)

 Age

39.0 ± 10.0

 Female (n, %)

15 (79%)

 BMI

26.8 ± 6.2

 Educational level (University educated n, %)

12 (63.1%)

Migraine Characteristics (mean ± SD)

 Duration (years)

21.0 ± 11.0

 Aura (n, %)

12.0 (66.7%)

 Pain intensity in last week (NRS %)

66.1 ± 22.9

 Escalated with CGRP-mAbs (n, %)

10.0 (55.6%)

Psychological Status (mean ± SD)

 DASS total score (range: 0 to 126)

21.6.0 ± 14.0

 - Depression (range: 0 to 42)

4.4 ± 5.7

 - Anxiety (range: 0 to 42)

6.0 ± 5.4

 - Stress (range: 0 to 42)

11.2 ± 6.1

Symptoms (median (IQR))

 Pain at time of 1st scan [NRS %]

40.0 (10.0 to 60.0)

 Pain at time of 2nd scan [NRS %]

10.5 (0.0 to 50.0)

 Time since migraine 1st scan [hours]

11.0 (0.0 to 48.0)

 Time since migraine 2nd scan [hours]

36.0 (4.0 to 168.0)

 Central Sensitisation Inventory˄ (range: 0 to 100)

45.0 (36.0 to 50.0)

Baseline Clinical status (mean ± SD)

  Migraine frequency (days per month)

16.7 ± 5.1

  WHODAS 2.0 (range: 12 to 60)

24.8 ± 16.1

  HIT-6 ǂ (range: 36 to 78)

65.7 ± 6.6

  GABA+ ACC [institutional units, IU]

4.51 ± 0.38

  GABA+ PCG [IU]

4.93 ± 0.62

 Glx ACC [IU]

13.51 ± 1.25

 Glx PCG [IU]

12.90 ± 1.86

  1. Clinical characteristics of participants included in final analysis (n = 18). Data reported as mean ± SD, except where stated non-normally distributed data is reported as Median (IQR). For DASS, CSI, WHODAS, HIT-6 a higher score indicates greater infliction. ˄CSI > 40 indicates central sensitization, ǂHit-6 score > 60 indicate severe impact.